دورية أكاديمية
أعرض في EDS

Preventing the adverse cardiovascular consequences of allogeneic stem cell transplantation with a multi-faceted exercise intervention: the ALLO-Active trial protocol.

التفاصيل البيبلوغرافية
العنوان: Preventing the adverse cardiovascular consequences of allogeneic stem cell transplantation with a multi-faceted exercise intervention: the ALLO-Active trial protocol.
المؤلفون: Dillon HT; Baker Heart and Diabetes Institute, Melbourne, Australia. hayley.dillon@baker.edu.au.; Institute for Physical Activity and Nutrition, School of Exercise and Nutrition Sciences, Deakin University, Geelong, Australia. hayley.dillon@baker.edu.au., Saner NJ; Baker Heart and Diabetes Institute, Melbourne, Australia., Ilsley T; Baker Heart and Diabetes Institute, Melbourne, Australia.; Central Clinical School, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Australia., Kliman D; Malignant Haematology and Stem Cell Transplantation Service, Alfred Hospital, Melbourne, Australia., Spencer A; Malignant Haematology and Stem Cell Transplantation Service, Alfred Hospital, Melbourne, Australia., Avery S; Malignant Haematology and Stem Cell Transplantation Service, Alfred Hospital, Melbourne, Australia., Dunstan DW; Baker Heart and Diabetes Institute, Melbourne, Australia.; Institute for Physical Activity and Nutrition, School of Exercise and Nutrition Sciences, Deakin University, Geelong, Australia.; Mary MacKillop Institute for Health Research, Australian Catholic University, Melbourne, Australia., Daly RM; Institute for Physical Activity and Nutrition, School of Exercise and Nutrition Sciences, Deakin University, Geelong, Australia., Fraser SF; Institute for Physical Activity and Nutrition, School of Exercise and Nutrition Sciences, Deakin University, Geelong, Australia., Owen N; Baker Heart and Diabetes Institute, Melbourne, Australia.; Centre for Urban Transitions, Swinburne University of Technology, Melbourne, Australia., Lynch BM; Baker Heart and Diabetes Institute, Melbourne, Australia.; Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Australia.; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Parkville, Australia., Kingwell BA; Baker Heart and Diabetes Institute, Melbourne, Australia.; CSL Ltd, Melbourne, Australia., La Gerche A; Baker Heart and Diabetes Institute, Melbourne, Australia., Howden EJ; Baker Heart and Diabetes Institute, Melbourne, Australia.
المصدر: BMC cancer [BMC Cancer] 2022 Aug 17; Vol. 22 (1), pp. 898. Date of Electronic Publication: 2022 Aug 17.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : BioMed Central, [2001-
مواضيع طبية MeSH: Hematologic Neoplasms* , Hematopoietic Stem Cell Transplantation*/adverse effects, Adult ; Australia ; Exercise Therapy/methods ; Fatigue/etiology ; Humans ; Quality of Life
مستخلص: Background: Allogeneic stem cell transplantation (allo-SCT) is a potentially lifesaving treatment for high-risk hematological malignancy, but survivors experience markedly elevated rates of cardiovascular disease and associated functional impairment. Mounting evidence suggests regular exercise, combined with a reduction in sedentary time through replacement with light exercise may be a useful therapeutic strategy for the prevention of cardiovascular comorbidities. However, this type of intervention has yet to be evaluated in patients undergoing allo-SCT. The ALLO-Active study will evaluate the efficacy of a ~ 4 month multi-faceted exercise intervention, commenced upon admission for allo-SCT, to preserve peak oxygen uptake (VO 2 peak) and peak cardiac output, compared with usual care. The study will also evaluate the effect of the intervention on functional independence, quality of life, and symptoms of fatigue.
Methods: Sixty adults with hematological malignancy scheduled for allo-SCT will be randomly assigned to usual care (n = 30) or the exercise and sedentary behaviour intervention (n = 30). Participants assigned to the intervention will complete a thrice weekly aerobic and progressive resistance training program and concomitantly aim to reduce daily sedentary time by 30 min with short, frequent, light-intensity exercise bouts. Participants will undergo testing prior to, immediately after inpatient discharge, and 12 weeks after discharge. To address aim 1, VO 2 peak and peak cardiac output (multiple primary outcomes, p < 0.025) will be assessed via cardiopulmonary exercise testing and exercise cardiac magnetic resonance imaging, respectively. Secondary outcomes include functional independence (defined as VO 2 peak ≥ 18.mL.kg -1 .min -1 ), quality of life, and fatigue (assessed via validated questionnaire). Exploratory outcomes will include indices of resting cardiac, vascular, and skeletal muscle structure and function, cardiovascular biomarkers, anxiety and depression, transplant outcomes (e.g., engraftment, graft-versus-host disease), and habitual physical activity, sedentary time, and sleep.
Discussion: Multi-faceted exercise programs are a promising approach for ameliorating the cardiovascular consequences of allo-SCT. If this intervention proves to be effective, it will contribute to the development of evidence-based exercise guidelines for patients undergoing allo-SCT and assist with optimising the balance between acute cancer management and long-term health.
Trial Registration: Australian New Zealand Clinical Trials Registry (ANZCTR), ID: 12619000741189 . Registered 17 May 2019.
(© 2022. The Author(s).)
References: Bone Marrow Transplant. 2014 Mar;49(3):443-8. (PMID: 24317122)
Circulation. 2003 Aug 5;108(5):554-9. (PMID: 12860904)
Eur J Appl Physiol. 2021 May;121(5):1487-1498. (PMID: 33638017)
Bone Marrow Transplant. 2018 Aug;53(8):983-992. (PMID: 29426831)
Circ Cardiovasc Imaging. 2013 Mar 1;6(2):329-38. (PMID: 23258478)
Adv Exp Med Biol. 2018;1072:293-298. (PMID: 30178361)
JACC CardioOncol. 2019 Dec 17;1(2):298-301. (PMID: 34396194)
Bone Marrow Transplant. 2014 Oct;49(10):1330-6. (PMID: 25068429)
Med Sci Sports Exerc. 2019 Nov;51(11):2375-2390. (PMID: 31626055)
Appl Physiol Nutr Metab. 2012 Oct;37(5):811-21. (PMID: 22735036)
Bone Marrow Transplant. 2010 Jan;45(1):149-52. (PMID: 19465940)
Acta Oncol. 2014 Jan;53(1):65-74. (PMID: 23957716)
Bone Marrow Transplant. 1996 Dec;18(6):1157-60. (PMID: 8971388)
Med Sci Sports Exerc. 2010 Jul;42(7):1409-26. (PMID: 20559064)
Sports Med. 2015 Feb;45(2):279-96. (PMID: 25281334)
Blood. 2007 Nov 15;110(10):3784-92. (PMID: 17671231)
N Engl J Med. 2006 Apr 27;354(17):1813-26. (PMID: 16641398)
Support Care Cancer. 2019 May;27(5):1793-1800. (PMID: 30155567)
Haematologica. 2008 Aug;93(8):1203-10. (PMID: 18556401)
Diabetes Care. 2012 May;35(5):976-83. (PMID: 22374636)
Biol Blood Marrow Transplant. 2014 Jun;20(6):794-800. (PMID: 24565992)
Cancer Nurs. 2017 May/Jun;40(3):174-183. (PMID: 27333126)
Diabetes. 2003 Aug;52(8):1888-96. (PMID: 12882902)
Biol Blood Marrow Transplant. 2018 Aug;24(8):1741-1747. (PMID: 29496561)
Am Heart J. 2017 Mar;185:35-42. (PMID: 28267473)
J Gerontol A Biol Sci Med Sci. 2006 Jun;61(6):534-40. (PMID: 16799133)
J Clin Oncol. 2009 Sep 20;27(27):4605-12. (PMID: 19687337)
Cancer Nurs. 2011 May-Jun;34(3):238-49. (PMID: 21116175)
Arthritis Care Res (Hoboken). 2011 Nov;63 Suppl 11:S350-70. (PMID: 22588756)
Support Care Cancer. 2018 Jun;26(6):1727-1736. (PMID: 29243166)
Circulation. 2010 Jul 13;122(2):191-225. (PMID: 20585013)
Eur J Prev Cardiol. 2012 Apr;19(2):151-60. (PMID: 21450580)
Oncologist. 2011;16(1):112-20. (PMID: 21212429)
Ann Intern Med. 2015 Jan 20;162(2):123-32. (PMID: 25599350)
Circ Heart Fail. 2016 Jan;9(1):e002661. (PMID: 26747861)
Eur J Cancer. 2013 Sep;49(13):2900-9. (PMID: 23706982)
Lancet. 2016 Sep 24;388(10051):1302-10. (PMID: 27475271)
Res Q Exerc Sport. 1999 Jun;70(2):113-9. (PMID: 10380242)
Eur Heart J. 2016 Sep 21;37(36):2768-2801. (PMID: 27567406)
Psychooncology. 2009 Apr;18(4):353-9. (PMID: 19117328)
Bone Marrow Transplant. 2009 May;43(9):725-37. (PMID: 19234513)
Bone Marrow Transplant. 2008 Feb;41(4):321-9. (PMID: 18026154)
Biol Blood Marrow Transplant. 2013 Jul;19(7):1073-80. (PMID: 23583827)
Eur J Haematol. 2011 Aug;87(2):148-56. (PMID: 21545527)
J Sci Med Sport. 2012 Jul;15(4):311-21. (PMID: 22306372)
Bone Marrow Transplant. 2011 Sep;46(9):1245-55. (PMID: 21132025)
JACC CardioOncol. 2022 Mar 15;4(1):19-37. (PMID: 35492815)
Circulation. 2017 Apr 18;135(16):e894-e918. (PMID: 28336790)
Circulation. 2001 Sep 18;104(12):1350-7. (PMID: 11560849)
J Clin Oncol. 2014 Jan 20;32(3):191-8. (PMID: 24297944)
Biol Blood Marrow Transplant. 2007 Aug;13(8):948-55. (PMID: 17640599)
J Appl Physiol (1985). 2015 Sep 15;119(6):734-8. (PMID: 26048977)
Bone Marrow Transplant. 2013 Oct;48(10):1342-9. (PMID: 23584437)
Can J Cardiol. 2016 Jul;32(7):926-30. (PMID: 27245087)
Scand J Med Sci Sports. 2008 Jun;18(3):354-9. (PMID: 18067524)
Med Sci Sports Exerc. 2009 Mar;41(3):687-708. (PMID: 19204579)
Nat Rev Cardiol. 2021 Sep;18(9):637-648. (PMID: 34017139)
Support Care Cancer. 2018 Jul;26(7):2149-2160. (PMID: 29372395)
Bone Marrow Transplant. 2006 May;37(10):945-54. (PMID: 16565742)
Asia Pac J Clin Oncol. 2020 Nov;16 Suppl 8:58-207. (PMID: 33161624)
Blood. 2012 Nov 29;120(23):4505-12. (PMID: 23034279)
Nutr Metab Cardiovasc Dis. 2014 Sep;24(9):976-82. (PMID: 24875670)
Blood Adv. 2020 Dec 22;4(24):6283-6290. (PMID: 33351121)
Gerontology. 2009;55(2):217-23. (PMID: 19060453)
PLoS One. 2014 Oct 15;9(10):e110034. (PMID: 25333969)
Support Care Cancer. 2021 Oct;29(10):6039-6048. (PMID: 33786668)
Eur J Clin Nutr. 2011 Jan;65(1):140-2. (PMID: 20842171)
Med J Aust. 2018 Aug 20;209(4):184-187. (PMID: 29719196)
Br J Sports Med. 2014 Aug;48(16):1227-34. (PMID: 24144531)
J Appl Physiol (1985). 2005 Apr;98(4):1154-62. (PMID: 15772055)
Transplant Cell Ther. 2021 Jun;27(6):483.e1-483.e6. (PMID: 33775615)
J Cardiovasc Magn Reson. 2010 May 11;12:26. (PMID: 20459799)
Med Sci Sports Exerc. 2013 Nov;45(11):2080-90. (PMID: 23669878)
Blood. 2009 Jul 2;114(1):7-19. (PMID: 19336756)
Blood. 2007 Nov 1;110(9):3463-71. (PMID: 17664354)
Ann Intern Med. 2011 Jul 5;155(1):21-32. (PMID: 21727290)
Eur J Prev Cardiol. 2019 Feb;26(3):305-315. (PMID: 30376366)
JACC CardioOncol. 2020 Sep 15;2(3):460-471. (PMID: 34396253)
Appl Physiol Nutr Metab. 2009 Jun;34(3):336-9. (PMID: 19448695)
J Appl Physiol (1985). 2014 Jun 1;116(11):1396-404. (PMID: 24744384)
Biol Blood Marrow Transplant. 2019 Jan;25(1):151-156. (PMID: 30103017)
N Engl J Med. 1995 Mar 2;332(9):556-61. (PMID: 7838189)
Am J Physiol Endocrinol Metab. 2008 Aug;295(2):E407-12. (PMID: 18544640)
معلومات مُعتمدة: 2019-1666 World Cancer Research Fund International
فهرسة مساهمة: Keywords: Allogeneic Stem Cell Transplant; Cardiovascular Health; Exercise training
تواريخ الأحداث: Date Created: 20220817 Date Completed: 20220819 Latest Revision: 20231103
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC9383666
DOI: 10.1186/s12885-022-09793-w
PMID: 35978289
قاعدة البيانات: MEDLINE
الوصف
تدمد:1471-2407
DOI:10.1186/s12885-022-09793-w